# Wegovy MASH: FDA Approval, Criteria, Dosing and New Data

Source: https://www.dietglp.com/blog/wegovy-mash/
Published: 2026-11-07
Keywords: wegovy mash, wegovy for mash, wegovy mash approval, wegovy mash indication, wegovy mash criteria, wegovy mash dosing, wegovy mash trial, wegovy mash fda approval date, is wegovy approved for mash, wegovy mash coverage, wegovy mash prior authorization, wegovy fatty liver, wegovy fatty liver coverage, can wegovy reverse mash, semaglutide vs resmetirom for mash

**TL;DR:** Yes, Wegovy is FDA approved for MASH, but only the weekly shot, only for adults, and only with moderate to advanced liver scarring (stages F2 to F3) and no cirrhosis. It is an accelerated approval from August 2025, based on liver biopsies at 72 weeks. New real-world data from November 2026 linked it to lower liver enzymes and weight, but those studies cannot prove cause. Weight loss still needs protein and strength work, and [Sharpy](https://apps.apple.com/us/app/glp-diet-app-sharpy/id6762084138) helps you track both.

Is Wegovy approved for MASH, and does it work? **Yes, the FDA approved the Wegovy shot for MASH in August 2025, for adults with moderate to advanced liver scarring (F2 to F3) and no cirrhosis. In its main trial, 63% of people had their liver inflammation resolve at 72 weeks, compared with 34% on placebo.** It is still an accelerated approval, so the long-term liver benefit has not been confirmed.

This guide covers who qualifies, the label dose, the trial, coverage, and the new data Novo Nordisk released on November 6, 2026.

## What is MASH?

MASH stands for metabolic dysfunction-associated steatohepatitis. It used to be called NASH. It means fat has built up in the liver and is causing inflammation and damage. Over time, that damage can leave scars, called fibrosis.

Novo says nearly 90% of people with MASH remain undiagnosed, because early MASH often causes few clear symptoms. Late-stage disease can lead to cirrhosis, liver cancer or a transplant. For the wider picture, see our [GLP-1 and fatty liver guide](/blog/glp1-and-fatty-liver/).

| Scarring stage | What it means | Wegovy for MASH label? |
|---|---|---|
| F0 to F1 | None or mild | Not included |
| F2 | Moderate | Included |
| F3 | Advanced | Included |
| F4 | Cirrhosis | Not included |

## Wegovy MASH indication: who it is for

The label covers adults with noncirrhotic MASH with moderate to advanced fibrosis, "consistent with stages F2 to F3." It is used along with a reduced calorie diet and more physical activity.

Three limits are easy to miss:

- **Only the shot.** The label says Wegovy tablets have not been established for MASH.
- **Not 7.2 mg.** Wegovy HD 7.2 mg has also not been established for MASH.
- **Not for teens.** The MASH use is for adults only.

The label also notes limited information in people with MASH and a BMI under 25. In the trial, the median BMI was 34.

## Wegovy MASH dosing, per the label

| Weeks | Once-weekly shot |
|---|---|
| 1 to 4 | 0.25 mg |
| 5 to 8 | 0.5 mg |
| 9 to 12 | 1 mg |
| 13 to 16 | 1.7 mg |
| 17 onward | 2.4 mg maintenance |

If 2.4 mg is not tolerated, the label says the dose can drop to 1.7 mg, and to consider going back up to 2.4 mg. Do not change your dose on your own. Talk to your prescriber.

## Wegovy MASH trial: what ESSENCE showed

The approval rests on the first part of ESSENCE, a phase 3 trial published in the New England Journal of Medicine. It enrolled 1,197 people with biopsy-proven MASH and F2 or F3 scarring. The week 72 biopsy results come from the first 800 people.

| Result at 72 weeks | Wegovy 2.4 mg | Placebo |
|---|---|---|
| Inflammation resolved, scarring no worse | 62.9% | 34.3% |
| Scarring improved, inflammation no worse | 36.8% | 22.4% |
| Both improved | 32.7% | 16.1% |
| Average weight change | -10.5% | -2.0% |

More than half of the people in this analysis (56%) had type 2 diabetes. The second part of ESSENCE is still running. It tests whether Wegovy lowers the risk of liver-related events, such as serious complications, over 240 weeks. Biopsy results are a stand-in for those events, which is why this is an accelerated approval.

## New Wegovy MASH data from The Liver Meeting 2026

On November 6, 2026, Novo released two real-world studies from the AASLD meeting in Denver. Both used medical records from the Truveta database, from June 2021 through March 2026.

| Measure | Wegovy 2.4 mg | Comparison | Significant? |
|---|---|---|---|
| **PLATINUM-Truveta, 6 months** | n=2,873 | Resmetirom, n=2,285 | |
| AST (U/L) | -10.4 | -4.5 | Yes |
| ALT (U/L) | -14.8 | -11.6 | No (P=0.20) |
| Weight (lb) | -18.9 | -5.6 | Yes |
| HbA1c (points) | -0.38 | -0.08 | Yes |
| LDL cholesterol | -13.7 | -29.1 | Yes, favors resmetirom |
| **RHODIUM-2, 12 months** | n=2,479 | No semaglutide, n=70,702 | |
| ALT (U/L) | -14.0 | -3.8 | Yes |
| AST (U/L) | -9.1 | -1.8 | Yes |
| Weight (lb) | -30.7 | -2.4 | Yes |

ALT and AST are blood tests of liver stress. Lower numbers are a good sign, but they are not the same as less scarring.

Read these numbers with care:

- **Treatment was not randomized.** Novo says the groups differed at the start and that cause and effect cannot be proven.
- **Only people who stayed on treatment counted.** People who quit, perhaps because of side effects, drop out of the math.
- **Novo announced the results.** HCPLive noted the release did not report fibrosis measures, confidence intervals or safety data.
- **These were meeting abstracts.** Novo says the data may change in a final paper.

Novo also scheduled a talk for November 8 on ESSENCE patients with a BMI under 27. Those results were not public when we wrote this.

## Wegovy vs Rezdiffra for MASH

Rezdiffra (resmetirom) was the first drug approved for MASH, in 2024. It works differently, acting on a thyroid hormone receptor in the liver. The two trials used different timelines and methods, so do not compare their percentages head to head.

| | Wegovy | Rezdiffra |
|---|---|---|
| Form | Weekly shot | Daily tablet |
| Dose | Up to 2.4 mg | 80 mg, or 100 mg at 100 kg and over |
| Approved stage | F2 to F3, no cirrhosis | F2 to F3, no cirrhosis |
| Approval type | Accelerated | Accelerated |
| Inflammation resolved vs placebo | 63% vs 34% (week 72) | 80 mg: 26 to 27%; 100 mg: 24 to 36%; placebo: 9 to 13% (month 12) |
| Scarring improved vs placebo | 37% vs 22% (week 72) | 80 mg: 23%; 100 mg: 24 to 28%; placebo: 13 to 15% (month 12) |
| Also helps weight loss | Yes, labeled use | Not a weight-loss drug |

Rezdiffra's ranges come from two pathologists who each read the biopsies, as shown on its label. Whether to use one, the other, or both is a question for a liver specialist. At least one plan below will not pay for both together.

## Wegovy MASH criteria and prior authorization

There is no single rule. Here is what two real plans ask for:

| Requirement | Maryland Physicians Care (Medicaid, Feb 2026) | Mass General Brigham Health Plan (commercial, Jul 2026) |
|---|---|---|
| Age | 18 or older | 18 or older |
| Stage proof | F2 or F3 by biopsy or noninvasive test, within 180 days | FIB-4 of 1.3 or more plus ELF or FibroScan; or FAST, MAST, MEFIB, or a biopsy within 12 months |
| Cirrhosis | Not allowed | Not allowed |
| Other MASH drugs | Not at the same time | Not with Rezdiffra |
| Prescriber | Gastroenterologist or hepatologist, or in consultation | Not in the part we reviewed |
| Diabetes | The form stops if the patient has diabetes | Not with a diabetes GLP-1 |

Ask your plan for its own form before your visit. Bring your liver test results, and ask whether a recent test is needed. If you are on Medicare, the [Medicare GLP-1 Bridge](/blog/medicare-glp-1-bridge/) is not the route for fatty liver disease, and your Part D plan decides coverage.

## Wegovy MASH cost without insurance

NovoCare listed the Wegovy pen at $349 a month for 0.25 mg through 2.4 mg when we checked on November 7, 2026. New patients can pay $199 for each of the first two fills at 0.25 mg and 0.5 mg, through December 31, 2026. NovoCare says pricing will be updated after that date. People with commercial coverage may pay as little as $25 a month, with a $100 monthly savings cap and eligibility rules. Check the current terms, since they may not fit every use. See [Ozempic price cut 2027](/blog/ozempic-price-cut-2027/) for coming list price changes.

## Wegovy MASH side effects

The label says the most common side effects in the MASH trial matched those in other Wegovy uses, such as stomach problems. Two MASH-specific numbers stand out:

- **Fractures:** 4.4% on Wegovy vs 3.3% on placebo.
- **High lipase,** a pancreas enzyme, over 3 times the normal limit: 4.7% vs 1.3%. The label says its meaning is unknown without signs of pancreatitis.

Wegovy has a boxed warning about thyroid C-cell tumors. If you are pregnant or planning to be, talk with your doctor. Get urgent care for severe belly pain that will not go away, or for yellow skin or eyes.

## Protect your muscle while your liver heals

Wegovy's MASH label pairs the drug with diet and activity, and the weight loss is real. But not all of it is fat. In a body-scan part of the STEP 1 trial, lean mass made up about 39% of the weight lost. MASH patients in ESSENCE were a median age of 57, an age when muscle and bone matter even more.

Two habits help most: reach your [daily protein target](/blog/protein-target-on-glp1/) and do [resistance training](/blog/resistance-training-on-glp1/). [Sharpy](https://apps.apple.com/us/app/glp-diet-app-sharpy/id6762084138) turns that into one protein target and one 20-minute workout a day. Ask your liver doctor about alcohol and any diet limits too. If you have advanced scarring, your care team may set protein goals for you.

## What to ask your doctor

- What is my fibrosis stage, and which test showed it?
- Is Wegovy, Rezdiffra or another plan the best fit for me?
- Which blood tests will we repeat, and when?
- Will my plan need a specialist to sign off?

Track your weight trend, protein and workouts between visits so you have real numbers to share. [Sharpy](https://apps.apple.com/us/app/glp-diet-app-sharpy/id6762084138) gives you one daily Shape Score for that. It does not treat liver disease, and it does not replace your care team.

## Sources

- [Novo Nordisk: real-world Wegovy MASH studies at The Liver Meeting 2026 (PR Newswire, Nov 6, 2026)](https://www.prnewswire.com/news-releases/novo-real-world-studies-link-wegovy-2-4-mg-to-reductions-in-liver-enzymes-weight-and-blood-sugar-in-adults-with-mash-at-the-liver-meeting-aasld-2026--302932360.html)
- [Novo Nordisk: liver data planned for AASLD 2026 (Oct 28, 2026)](https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=919208)
- [HCPLive: Semaglutide linked to lower liver enzymes and weight (Nov 6, 2026)](https://www.hcplive.com/view/semaglutide-linked-to-lower-liver-enzymes-weight-in-real-world-mash-data)
- [Wegovy prescribing information, June 2026 (DailyMed)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b)
- [Sanyal et al. Phase 3 trial of semaglutide in MASH. NEJM 2025 (PubMed)](https://pubmed.ncbi.nlm.nih.gov/40305708/)
- [HCPLive: FDA approves semaglutide for noncirrhotic MASH (Aug 15, 2025)](https://www.hcplive.com/view/fda-approves-semaglutide-wegovy-injection-2-4-mg-for-noncirrhotic-mash)
- [Rezdiffra prescribing information (Madrigal)](https://www.madrigalpharma.com/Rezdiffra-USPI)
- [Maryland Physicians Care: Wegovy prior authorization form](https://www.marylandphysicianscare.com/wp-content/uploads/2026/03/Wegovy-MPC.pdf)
- [Mass General Brigham Health Plan: weight loss medication policy (Jul 2026)](https://resources.massgeneralbrighamhealthplan.org/pharmacy/PharmacyPolicies/CommercialPolicies/WeightLossMedications_PA_ComExch_Rx_07.01.2026.pdf)
- [NovoCare: Wegovy savings offer](https://www.novocare.com/obesity/products/wegovy/savings-offer.html)
- [Wilding et al. STEP 1. NEJM 2021](https://www.nejm.org/doi/full/10.1056/NEJMoa2032183)


## Frequently asked questions

**Q: Is Wegovy approved for MASH?**

A: Yes. The FDA granted accelerated approval in August 2025. It covers the Wegovy injection for adults with noncirrhotic MASH and moderate to advanced liver fibrosis, consistent with stages F2 to F3. Full approval may depend on a confirmatory trial that is still running.

**Q: What is the Wegovy dose for MASH?**

A: Per the label, the shot starts at 0.25 mg once a week and steps up every 4 weeks through 0.5 mg, 1 mg and 1.7 mg. The maintenance dose is 2.4 mg once a week. If 2.4 mg is not tolerated, the label allows 1.7 mg, and the prescriber may consider going back up. Your prescriber sets your schedule.

**Q: Can Wegovy reverse MASH?**

A: In the ESSENCE trial, 63% of people on Wegovy had their steatohepatitis resolve without worse scarring at 72 weeks, compared with 34% on placebo. Scarring improved in 37% compared with 22%. That means many people improved on a biopsy, not everyone. It is not yet proven that Wegovy prevents cirrhosis or liver failure.

**Q: Is the Wegovy pill approved for MASH?**

A: No. The label says the safety and effectiveness of Wegovy tablets have not been established in patients with MASH. The same is true of the 7.2 mg shot. Novo has submitted the pill to the FDA for MASH, but no decision had been reported when we wrote this.

**Q: Does insurance cover Wegovy for MASH?**

A: Some plans do, usually with prior authorization. Plans we read ask for proof of stage F2 or F3 by biopsy or noninvasive test, age 18 or older, and no cirrhosis. Rules differ a lot, so ask your plan for its current form.

**Q: Is Wegovy better than Rezdiffra for MASH?**

A: Nobody knows yet. No randomized trial has compared them directly. A November 2026 real-world study linked Wegovy to more weight loss and a bigger AST drop, while LDL cholesterol fell more on resmetirom and the ALT difference was not significant. Your liver doctor can help weigh them.

**Q: Can I take Wegovy for MASH if I have cirrhosis?**

A: The approved use does not include cirrhosis. If you have cirrhosis or have been told your scarring is stage F4, talk with a liver specialist about your options.